Journal of Parkinsons Disease

Papers
(The H4-Index of Journal of Parkinsons Disease is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline115
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects107
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations68
Parkinson’s Disease and the COVID-19 Pandemic67
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future62
Infection and Risk of Parkinson’s Disease62
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update60
Preventing Parkinson’s Disease: An Environmental Agenda56
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead53
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update45
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis43
Global Perspective on Telemedicine for Parkinson’s Disease41
Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes41
Digital Therapeutics in Parkinson’s Disease: Practical Applications and Future Potential40
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?39
Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review38
Oral Dysbiosis and Inflammation in Parkinson’s Disease35
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)35
Proposal for a Biologic Staging System of Parkinson’s Disease35
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study34
Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts34
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOV33
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture32
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective32
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results31
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations31
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study31
Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson’s Disease: A Randomized Controlled Trial30
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions30
A Practical Approach to Early-Onset Parkinsonism29
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update29
T Lymphocytes in Parkinson’s Disease29
0.032463073730469